Interestingly, blocking TM4SF1 with a specific antibody reduces the growth and increases cisplatin cytotoxicity in ARID1A-depleted NSCLC cells, which is coupled with inhibition of Akt activation. The gene discussed is TM4SF1; the disease is non-small cell lung carcinoma.